Susan Blumel

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

Jonathan W. Friedberg, Julie M. Vose, Jennifer L. Kelly et al. · Blood · 2011 · 192 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Patients with chemotherapy‐refractory mantle cell lymphoma experience high response rates and identical progression‐free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial

Owen A. O’Connor, Craig H. Moskowitz, Carol S. Portlock et al. · British Journal of Haematology · 2009 · 83 citations

Medicine, Oncology, Pharmacotherapy +16

Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes

Owen A. O’Connor, Carol S. Portlock, Craig H. Moskowitz et al. · Clinical Cancer Research · 2010 · 44 citations

Medicine, Hematology, Pharmacology +16

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

Owen A. O’Connor, James R. Wright, Craig H. Moskowitz et al. · Blood · 2004 · 16 citations

Medicine, Oncology, Pharmacology +14

Bendamustine: A Novel Cytotoxic Agent for Hematologic Malignancies

Susan Blumel, Amy Goodrich, Cheryl Martin et al. · Clinical journal of oncology nursing · 2008 · 14 citations

Medicine, Oncology, Pharmacology +13